NMN vs NMNH: 10x Potency? Clinical Studies Uncover Truth

What is NMNH?

NMNH, or reduced nicotinamide mononucleotide (reduced NMN), is the hydrogenated form of NMN. While it shares a similar function with NMN, its chemical structure is fundamentally different. Early studies introduced NMNH as a next-generation NAD+ booster with impressive potential. Laboratory research found that NMNH significantly increased NAD+ levels in a variety of cell types, consistently outperforming NMN when given at the same dosage. This suggests that NMNH could be a stronger and more efficient option for NAD+ supplementation. In animal studies, NMNH not only led to a rapid rise in NAD+ levels in the bloodstream, but also maintained elevated NAD+ in critical organs such as the liver, kidneys, brain, and heart.

These preclinical results are the foundation of the widely circulated claim that “NMNH is 10 times more effective than NMN.” However, it’s important to note that these findings come only from cell and animal models. Human clinical research has only recently begun—and the early results offer a more grounded and realistic perspective.

NMNH vs NMN: Key Differences

Although both of these compounds have the ability to upregulate NAD+, their various constructs lead to potentially different biological actions. NMNH (reduced NMN) is actually not just a modified NMN but it is a different compound. NMNH, being in a reduced state, may be able to give faster and more effective NAD+ production in cells, yet the exact metabolic pathway in the body is still a subject of research.

Commercially, the stability of NMNH has been a challenge due to its being vulnerable to oxidation. UthPeak® has come up with this, using its special crystalline form, purity and shelf life were granted which are the main differences from ordinary NMNH products.

Most importantly, UthPeak®’s Phase I clinical trial demonstrated that taking NMNH daily for 90 days led to a 3-fold increase in NAD+ levels. While that may not be as eye-catching as the “10x” lab-based claim, it represents the first real human data and is highly compelling. The same study also reported a 5-year reduction in biological age, a 35% increase in energy perception, and a 31% improvement in emotional well-being—outcomes that far exceeded those observed in preclinical models.^[1]

Is NMNH Better Than NMN?

While NMNH brings the NMNH (reduced NMN) promising results, it is not exactly the same thing as NMN. Both compounds still retain their respective positions in the NAD+ phase of the project and are safe to use. Nevertheless, NMN has a longer history of clinical use, while NMNH is in its early stages of research. Despite this fact, UthPeak® NMNH is currently the only NMNH supplement that has been tested on humans, providing a practical view of its possible uses.

The “10x potency” label may have fueled early interest, but clinical evidence gives us a clearer, more reliable benchmark—up to 3x NAD+ elevation in humans. That alone is a powerful result and a big step forward in longevity science.

Best NMNH Supplement: What to Look For

As NMNH (reduced NMN) continues to gain popularity, not all products on the market are created equal. Many NMNH powders suffer from low purity and poor stability. To ensure both safety and efficacy, it’s essential to choose supplements that are third-party tested, manufactured in GMP-certified facilities, and supported by clinical research.

UthPeak® NMNH meets all of these criteria. It remains the only NMNH supplement with published human safety and efficacy data. Dosages between 125mg and 500mg have been found to be both safe and effective, with no severe side effects. Still, anyone with a medical condition or who is pregnant should consult a physician before use.

NMNH vs NMN: Side Effects & Safety

Both NMN and NMNH (reduced NMN) are generally regarded as safe. NMN is well-studied and typically well-tolerated, although some users report mild digestive discomfort. In contrast, NMNH—particularly in its UthPeak® crystalline form—has shown excellent tolerability in Phase I trials, with no major adverse effects reported. Its Self-GRAS certification further reinforces its safety profile as a daily NAD+ enhancer.

NMN vs NMNH in chemical structure

NMNH Research & Clinical Trials

NMNH (reduced NMN) is still a relatively new molecule in the field of human clinical research. UthPeak® led the first-ever Phase I clinical trial evaluating NMNH’s safety and effectiveness in healthy adults. The results—highlighting a 3X increase in NAD+ levels, along with notable anti-aging effects—mark a significant milestone and will be published soon.

Building on these findings, a Phase II clinical trial is currently ongoing, with a full-scale rollout planned for 2025. This next phase will focus on validating NMNH’s broader health benefits in a larger population, particularly in key areas such as cardiovascular protection, liver function support, and energy enhancement. The goal is to generate deeper insights into how NMNH supplementation may improve long-term well-being.

Where to Find Published Data?

Ongoing updates will be released on the UthPeak® official website, the EffePharm homepage, and across our verified social media platforms.
You can also track study progress and clinical trial documentation by searching the National Clinical Trial (NCT) number: NCT06889740 on ClinicalTrials.gov..

For partnership opportunities, detailed findings, or media inquiries, please contact us directly for the most up-to-date research access.

The Next Step in Longevity Science Starts with NMNH

NMNH is emerging as one of the most promising molecules in the field of NAD+ supplementation. Although the claim of “10x” potency stems from animal studies, human trials—particularly UthPeak®’s—show that NMNH can significantly increase NAD+ levels by up to 3 times. With additional benefits tied to energy, emotional wellness, and biological aging, the outlook is strong.

For consumers looking to take advantage of cutting-edge science, NMNH supplements—especially those like UthPeak® backed by clinical data—offer a credible and exciting option.

FAQ

Is NMNH the same as NMN?

No, they are different compounds. NMNH, also known as reduced NMN, has a different chemical structure. While both help increase NAD+ levels, NMNH may be absorbed and processed differently in the body. Recent research suggests that its reduced form could make it more efficient in boosting NAD+ naturally.

Does NMNH really increase NAD+ 10 times more?

The “10x” figure comes from lab and animal studies. In real-world human trials, NMNH (reduced NMN) has been shown to raise NAD+ levels by up to 3 times over 90 days. These results come from early-stage clinical research and represent the most realistic outcome to date. You can follow progress via NCT Number: NCT06889740.

Where can I buy the best NMNH supplement?

Choose high-purity, clinically tested NMNH (reduced NMN) supplements from trusted providers. UthPeak® NMNH is currently the only reduced NMN supplement backed by human clinical data. You can visit our Where to Buy page to find reliable brand partners.

What are the NMNH vs NMN side effects?

Current research suggests that the side effects induced by NMN are not pronounced. NMN, just like other NAD+ enhancing agents, is basically without side effects if it is taken as prescribed. Actually, a scientific review on the NAD+ precursors has given a green light to the use of compounds similar to NMN and NR in both animal and human studies, which showed no adverse effects^[2]. As a matter of fact, few people have mentioned any adverse effects, while others may get mild health issues in the form of a headache or tiredness. In case you are pregnant, breastfeeding, or on medication, you should consult your physician.

References：

[1] UthPeak®. (n.d.). A Study to Evaluate the Safety and Efficacy of NMNH Supplementation in Healthy Adults (NCT06889740). ClinicalTrials.gov. Retrieved from https://clinicaltrials.gov/study/NCT06889740

[2] Rajman, L., Chwalek, K., & Sinclair, D. A. (2018). Therapeutic potential of NAD+-boosting molecules: the in vivo evidence. Cell Metabolism, 27(3), 529–547. https://doi.org/10.1016/j.cmet.2018.02.011